Search Videos and More
News
New Targeted Treatments Emerge for Gastric and Esophageal Cancer
For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options.
News
Obesity and High Weight Linked to Adverse Outcomes In Leukemia Treatment
As the United States faces a growing obesity epidemic, scientists are taking a closer look at how body weight can affect health outcomes.
News
ChatGPT and Medicine: The Good, the Bad, and the Bizarre
The artificial intelligence chatbot ChatGPT has wowed users with its seemingly human-like ability to generate and respond to language, and worried others by that very same ability.
News
Making Natural Killer Cells Smarter to Improve Cell Therapy
Could natural killer cells build the foundation for a new vision of immunotherapy?
Document
Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
Video
ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2023.
Video
ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.
Video
ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2023.
Course
Breast Cancer: New Horizons, Current Controversies
July 20-22, 2023 Live Virtual and In Person Westin Copley Place, Boston, MA
News
Dana-Farber Research Publication, 7.1.2023
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.
News
Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients Should Know
In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
News
Study Suggests Lymphoma Patients with Depression or Anxiety Experience Shorter Survival Times
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology.